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Congenital myopathies (CMs) caused by mutation in cofilin-2 gene (CFL2) show phenotypic 
heterogeneity ranging from early onset and rapid progressive forms to milder myopathy. Muscle 
histology is also heterogeneous showing rods and /or myofibrillar changes. Here, we report on three 
new cases, from two unrelated families, of severe CM related to novel homozygous or compound 
heterozygous loss-of-function mutations in CFL2. Peculiar histopathological changes showed 
nemaline bodies and thin filaments accumulations together to myofibrillar changes, which were 
evocative of the muscle findings observed in Cfl2-/- knockout mouse model.   
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Nemaline myopathies (NM), constitute a family of rare congenital disorders of skeletal muscle thin 
filaments characterized by the presence of nemaline bodies (rods) on muscle biopsy.1  So far, 
mutations in 12 different genes have been reported to cause autosomal dominant (AD) or autosomal 
recessive (AR) forms of NM 2-14. Cofilin-2 is a widely expressed member of the AC group of 
proteins that regulate actin-filament dynamics 15. It binds to and depolymerizes filamentous F-actin, 
and negatively controls polymerization of monomeric G-actin in a pH-dependent manner 16. 










Biallelic mutations in CFL2 are a rare cause of an AR form of NM (MIM #610687). The few 
reported cases are clinical and morphological heterogeneous leading to early-onset and rapidly 
progressive phenotype to a milder condition characterized by limb girdle and axial muscle 
weakness 8, 17, 18. Muscle histology shows features of nemaline or myofibrillar myopathy (MFM), as 
well as coexistence of both of these histopathological changes 17. Complete loss of cofilin-2 
function is generally associated to a severe phenotype however the precise mechanism through 
which cofilin-2 defect leads to different structural abnormalities remains elusive. 
Here we report on the clinical and myopathological findings in three patients from two unrelated 
families harboring novel mutations in CFL2, who presented an early-onset, severe form of 
congenital myopathy with peculiar histopathological findings of nemaline bodies and thin filaments 
accumulation. 
Detailed information about methods are reported in appendix S1 (supplementary file). 
 
Ethics statement 
The clinical and molecular genetic study was performed in accordance with the Declaration of 
Helsinki. Studies of muscle biopsies and molecular genetic analysis have been approved by our 
ethics committee with written informed consent obtained for each patient.  
 
RESULTS 
Clinical history and muscle pathology 
Patient 1 is a 7 year-old boy, first child of healthy consanguineous parents, presenting severe 
generalized muscle weakness that required continuous respiratory and nutritional support since 
birth.  Neurological examination performed at the age of 4 years documented facial weakness that 
spared only extraocular muscles, macroglossia, and severe and generalized muscle weakness. 
Muscles masses appeared diffusely hypertrophic and with hardened consistency. Brain RMI, ECG 
and echocardiography were normal. 










Patient 2 is a 1 year-old female, third child of non-consanguineous healthy parents. At age 20 days, 
she was admitted in ER for apnea episode and suction deficit with probable dysphagia. Clinical 
evaluation documented severe generalized hypotonia. Brain ultrasound, ECG and echocardiography 
were normal. Cranial nerves were spared. Only small distal movements of upper limbs were 
possible. Lower limbs were plegic, abducted and extra-rotated.  
Patient 3, the older affected brother of Pt2, had a similar clinical picture and died at the age of 3 
months for respiratory failure.  
Clinical features of all patients are summarized in Table 1.  
Muscle biopsy was performed at the age of 4 years in Pt1, 2 months in Pt2 and 23 days in Pt3. In all 
patients rods were observed. In Pt1 and Pt2 myopathic changes were more pronounced and small 
areas of myofibrillar dissolution together to thin filaments accumulation and cytoplasmic bodies 
(Pt1) were  documented. ATPase reactions showed a type 1 fiber predominance only in Pt3 and 
immunostaining for dystrophin, sarcoglicans and merosin was normal (data not shown). Detailed 
morphological features are showed in Fig. 1-I-III. 
Laboratory results 
Whole Exome Sequencing (WES) in Pt1 and targeted resequencing using a custom gene panel for 
muscular diseases in Pt2, allowed us to identify three novel mutations in exon 2 of CFL2:  
c.256G>C; p.(Asp86His), homozygous in Pt1, and c.235G>T; p.(Asp79Tyr) and c.281delC; 
p.(Ser94LeufsTer6) in compound heterozygosity in Pt2. Sanger sequencing confirmed the 
mutations identified in probands and in Pt3, as well as heterozygosity for the mutations in their 
parents (Supplementary Fig. 1). 
Immunohistochemical and western blot, performed in Pt1, confirmed the cofilin-2 reduction in 
muscle (Fig. 2-I) and slightly increased of CFL2 mRNA level was documented (Supplementary 
Fig. 2) thus providing evidence for the disruptive impact of the p.(Asp86His) change.  










The structural impact of the two missense substitutions was also supported by the homology model 
of the human cofilin-2 that shows that these residues are engaged in intramolecular interactions 
important for the folding of cofilin-2 in the region mediating the binding to actin (Fig. 2-III). 
DISCUSSION 
Congenital myopathies related to CFL2 mutations are rare congenital disorders with wide clinical 
and myopathological heterogeneity. CFL2 encodes for cofilin-2 that, together with cofilin-1 and 
ADF/destrin, promotes actin-filament turnover in cells 19, 20. ADF and cofilin-1 regulate actin 
filament dynamics at filament ends 21, while cofilin-2 has a higher affinity for filamentous actin and 
a slightly reduced actin-filament depolymerization activity 20, 22.  
Several morphological features like nemaline bodies, minicores, concentric laminated bodies and 
areas of F-actin accumulation have been reported in patients carrying mutations in CFL2. These 
mixed phenotypes, overlapping nemaline and myofibrillar myopathies, suggest that expression of 
mutated forms of cofilin-2 is causal to sarcomeric and extrasarcomeric cytoskeletal pathologies 17, 
and highlights the functional importance of cofilin-2 for F-actin depolymerizing activity and for the 
structural integrity of skeletal muscle tissue.  
A knock-out mouse model of CFL2 was recently generated by Gurniak and collaborators 23 to more 
precisely explore the physiological function of cofilin-2. In the Cfl2−/− model, myofibers and 
sarcomeric structures were initially formed correctly even in the absence of cofilin-2. However, 
within a few days after birth, sarcomeric structures progressively undergo derangement, start to 
disintegrate, and pathological protein aggregates appear, without evidence of nemaline bodies 
formation. Thus, the Cfl2−/− mouse rapidly develops all the hallmarks of a protein aggregate 
myopathy, similarly to what has been described in patients with homozygosity for the p.(Val7Met)  
change 17.  










We describe three patients from two unrelated families, who presented an early and severe form of 
CM related to mutations in CFL2. Only three CFL2-related NM families have been reported so far, 
all carrying homozygous mutations in CFL2 associated with partial or complete cofilin-2 
deficiency. Similarly to the present findings, also in the previously reported cases has been 
demonstrated that the missense mutations had a pathogenetic role leading to a misfolding and 
accelerated protein degradation 8, 17. Consistently, nonsense-mediated decay has been reported for 
CFL2 truncating changes 18, strongly pointing to loss of CFL2 function as the underlying 
mechanism of disease. 
Muscle biopsies showed in all patients of our series myopathic changes with atrophic and 
hypertrophic myofibers, internalization of myonuclei and multiple nemaline bodies, and 
accumulation of thin filaments were also documented mainly in Pt1 and Pt2. Moreover, fibrosis, as 
well as sarcomeric disruption, were more pronounced in the oldest patient with the homozygous 
CFL2 p.(Asp86His) confirming the observation of  Ockeloen and collaborators 17 that the pathology 
associated with CFL2 mutations may evolve from NM phenotype at younger ages, towards one 
more closely pattern resembling MFM with increasing age. These results mirror the pathologic 
evolution of Cfl2−/− mice which, despite are normal at birth, rapidly develop a severe myopathy 
with thin filaments aggregates 23. 
 
Conclusion 
We report three new severe cases of CM related to novel inactivating mutations in CFL2. Only for 
the cases with null mutations18, our patients were more severely affected than previously reported 
families with CFL2 missense mutations 8, 17. Morphological features, consistent of thin filaments 
accumulations and myofibrillar changes, are evocative of the histopathological findings observed in 
Cfl2-/- mouse model. Structural modeling analysis supports the pathogenicity of the three novel 
CFL2 mutations and indicates that mutated residues are involved in correct folding of cofilin-2, thus 
compromising its interaction with actin filaments. This observation may explain the myofibrillar 










network disintegration that we observed in our patients and confirms that the activity of cofilin-2, to 
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I: Thricrome Gomori (A, for Pt1, B for Pt2, C and F for Pt3) shows myopathic changes with fiber 
size variability, internal nuclei, presence of numerous small atrophic fibers and increased fat and 
connective tissue in all patients. In Pt1 prominent endomysial fibrosis and few fibers with vacuolar 
changes and cytoplasmatic bodies are observed (A). In Pt1 and Pt2 in  larger fibres  areas of green 
cytoplasmic material can be noted (A-B) . Nemaline bodies can be observed in Pt1 (A, arrow) and 
are numerous and more evident in Pt3 (C and F).  










Abnormal sarcomere myofibrillar network and numerous area with uneven oxidative reaction can 
be documented in Pt1 and Pt2 with NADH staining (D and E respectively) and correspond to the 
area of thin filaments accumulation showed in Fig.1-II.  
II: Fluorescence analysis reveals in both patients the myofibrillar network disorganization 
documented by the irregular immunostaining for desmin. Numerous areas positive for phalloidin 
and myotilin are indicative of F-actin-filaments accumulations. In both patients a diffuse reduction 
of cofilin-2 is also shown and spots of protein aggregations are observed in some fibers. Bar 50 μm. 
III:  Skeletal muscle ultrastructure shows in Pt1 (A-D) a wide array of myofibrillar changes 
including large areas of sarcomeric dissolution with accumulations of thin filaments and rods, 
cytoplasmic bodies, and autophagic vacuoles filled with membranous debris. Accumulations of thin 
filaments, nemaline bodies and M- and Z-lines misalignment were also observed in Pt2 (E-F).  
 





















Figure 2:  
I: Western blot analysis from muscle of  Pt1 shows a reduction >50% of cofilin-2 compared to the 
median value of two unaffected, age-matched control (Ct) muscle specimens (A-B) indicating 
accelerated degradation of the mutated protein.  
II: (A) Multiple alignment between cofilin-2 and the other actin depolymerizing factors expressed 
in mouse and human (CFL1 and DSTN) showing that aspartate residues (D79 and D86, red arrows) 
altered in our patients are evolutionarily conserved among AC proteins. (B) Schematic diagram of 
CFL2 gene with previously reported (black) and presently identified (red) CFL2 mutations. 
Mutations reported in a compound heterozygous state are underlined.  
III: Homology model of the human cofilin-2 bound to actin filaments based on the structure of 
cofilin-2 from chicken (Protein Data Bank, PDB 1TVJ) and superimposed onto the structure of the 
paralogous cofilin-1 bound to actin filaments (PDB 3J0S). The protein monomers are shown in 
different colors (the cofilin molecules are indicated by rounded arrows). Both the residues implied 
in the p.(Asp79Tyr) and p.(Asp86His) mutations are expected to modify protein folding and to 
cause defective binding of cofilin-2 to actin filaments. The p.(Ser94LeufsTer6) mutation implies the 
alteration/loss of a large portion of cofilin-2 (residues 94-166) necessary for the interaction of the 














Table 1: Clinical features of patients presented in this study in comparison to previously reported 
families with CFL2 mutations. Abbreviations: y, year; m, month; NA, not available. 
 
 









eReference This study Agrawal et al,2007 Ockeloen et al, 2012 Ong  et al, 2014
CFL2 mutation p.[(Asp86Asn)];[(Asp86Asn)] p.[(Asp79Tyr)];[(Ser94LeufsX6)] p.[(Ala35Thr)];[(Ala35Thr)] p.[(Val7Met)];[(Val7Met)] p.[(Lys34GlnfsX6)];[(Lys34GlnfsX6)] 
Patient (age at examination) 
 
pt 1 (4ys) pt2 (1 y) pt 3 (1m) pt 1 (16ys) pt2 (2ys) pt 1 (21ys) pt 2 (5ys) pt 1 (1 m)









respiratory distress and apnea at 5 
days requiring intubation 
Floppy infant yes yes yes  yes no no no yes 
Respiratory distress at birth yes  
(tracheostomy at 2 months) 
yes 
(tracheostomy 
at 2 months) 
yes no no no  + yes 
Nutritional support yes  




NA no no no no yes
Motor development none  none none delayed delayed delayed 
walking 
normal until 
age 2 yrs and 7 
months 
compromised
Facial weakness yes no no NA NA high-arched 
palate, low-
pitched voice  
no NA




NA NA NA knees no NA





Muscle mass hypertrophy wasting wasting NA NA wasting normal NA
Distribution of weakness diffuse and symmetric diffuse and 
symmetric 







NA NA axial and 
proximal 







Best motor achievement and 
outcome 
none none none can walk 
short 
distances 







since age 21 
waddling gait 24-h continuous ventilation 
support. Died at 12 months 
Peculiar features macroglossia  -  -  -  -  head drop  -  - 
Cardiac involvement - - - NA NA - - -
CK  1500 600 800 NA NA normal NA mild elevation
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